AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16863773 — intervention group
Group type: COMPARATOR
Intervention: Both groups (on-pump and off-pump)
Number of subjects: 212
Study 15175031 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-5 monoclonal antibody (mepolizumab)
Number of subjects: 24
Study 15175031 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 11305700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone, average end‐of‐treatment dose 376 mg/day
Number of subjects: 993
Study 15251769 — intervention group
Group type: EXPERIMENTAL
Intervention: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin), administered twice daily for 4 weeks
Number of subjects: 90
Study 15251769 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin, administered twice daily for 4 weeks
Number of subjects: 90
Study 15251769 — intervention group
Group type: EXPERIMENTAL
Intervention: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin)
Number of subjects: 90
Study 15251769 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 90
Study 8327417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention strategies mediated through lay volunteers from participating churches
Number of subjects: 272
Study 8327417 — intervention group
Group type: COMPARATOR
Intervention: Minimal (self-help) intervention strategies
Number of subjects: 272
Study 3548733 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 3548733 — intervention group
Group type: COMPARATOR
Intervention: HLA-DR2
Number of subjects: 0
Study 31268211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multicomponent intervention including point‐of‐care FOBT provision, printed screening advice, and GP endorsement)
Number of subjects: 123
Study 31268211 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 123
Study 28364253 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prediabetes (n=63)
Number of subjects: 102
Study 28364253 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with normal glucose tolerance (NGT) (n=39)
Number of subjects: 102
Study 28364253 — intervention group
Group type: COMPARATOR
Intervention: Control participants (n=15)
Number of subjects: 102
Study 28364253 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prediabetes
Number of subjects: 102
Study 28364253 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with normal glucose tolerance (NGT)
Number of subjects: 102
Study 28364253 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 102
Study 25853533 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits conducted by family medicine residents
Number of subjects: 0
Study 25853533 — intervention group
Group type: COMPARATOR
Intervention: Routine office-based newborn care
Number of subjects: 0
Study 23740935 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and GVAX therapy
Number of subjects: 6
Study 21217449 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 209
Study 21217449 — intervention group
Group type: COMPARATOR
Intervention: Cervical total disc arthroplasty (TDA)
Number of subjects: 209
Study 19665354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n=6) - roughened implant surface by sandblasting only
Number of subjects: 18
Study 19665354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n=12) - implant surface with additional macroretentions
Number of subjects: 18
Study 17353819 — intervention group
Group type: EXPERIMENTAL
Intervention: SenSura bag
Number of subjects: 68
Study 17353819 — intervention group
Group type: COMPARATOR
Intervention: Reference bag
Number of subjects: 68
Study 14977029 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study 11759182 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN (5625 mg/vial) administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Number of subjects: 26
Study 11759182 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Number of subjects: 26
Study 9515241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) alone (n = 50)
Number of subjects: 98
Study 9515241 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy with operative cholangiography and (if necessary) bile duct exploration (n = 48)
Number of subjects: 98
Study 8070199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsing electromagnetic field stimulation
Number of subjects: 47
Study 8070199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pulsing electromagnetic field stimulation)
Number of subjects: 47
Study 3277419 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg once daily
Number of subjects: 30
Study 3277419 — intervention group
Group type: COMPARATOR
Intervention: Captopril 12.5 to 50 mg twice daily
Number of subjects: 30
Study 31161289 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP hernia repair
Number of subjects: 176
Study 31161289 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein hernia repair
Number of subjects: 176
Study 31018682 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 31018682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitors
Number of subjects: 0
Study 29354948 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated needle
Number of subjects: 60
Study 29354948 — intervention group
Group type: COMPARATOR
Intervention: Filiform needle
Number of subjects: 60
Study 29354948 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study 25955246 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (two doses)
Number of subjects: 31
Study 23670318 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Epley maneuver
Number of subjects: 0
Study 21256445 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance plus plyometric training
Number of subjects: 15
Study 21256445 — intervention group
Group type: COMPARATOR
Intervention: Endurance only training (control group)
Number of subjects: 15
Study 19229704 — intervention group
Group type: EXPERIMENTAL
Intervention: FORM + TIO
Number of subjects: 255
Study 19229704 — intervention group
Group type: COMPARATOR
Intervention: TIO
Number of subjects: 255
Study 16846545 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV 10 mg/day
Number of subjects: 120
Study 16846545 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV 20 mg/day
Number of subjects: 120
Study 16846545 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV 10 mg/day and ATV 20 mg/day
Number of subjects: 120
Study 16846545 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 120
Study 12775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide (FE(NO)) measurement
Number of subjects: 96
Study 12775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lung function and bronchodilator responsiveness measured using impulse oscillometry (IOS)
Number of subjects: 96
Study 12775859 — intervention group
Group type: COMPARATOR
Intervention: Baseline lung function
Number of subjects: 96
Study 12775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics (ROC) analysis of FE(NO)
Number of subjects: 96
Study 10862057 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Number of subjects: 5
Study 10862057 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 5
Study 9085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg x kg(‐1) x min(‐1)
Number of subjects: 10
Study 9085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 10
Study 9085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 microg x kg(‐1) x min(‐1)
Number of subjects: 10
Study 9085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg x kg(‐1) x min(‐1) after surgery
Number of subjects: 10
Study 8403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg)
Number of subjects: 60
Study 8403274 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) (6 mg/kg)
Number of subjects: 60
Study 6587752 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 6587752 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 6587752 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol
Number of subjects: 0
Study 30825880 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for GPs consisting of lectures and workshops aimed at increasing work awareness and proactive counseling for patients with work-related problems.
Number of subjects: 280
Study 30825880 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for GPs
Number of subjects: 280
Study 30825880 — intervention group
Group type: COMPARATOR
Intervention: Usual care by GPs in control group
Number of subjects: 280
Study 30203494 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigative device (Vesair Balloon) placement
Number of subjects: 0
Study 30203494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 26748631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal lifestyle intervention
Number of subjects: 401
Study 26748631 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 401
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy for colorectal cancer
Number of subjects: 0
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy for sarcoma
Number of subjects: 0
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy for melanoma
Number of subjects: 0
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy for non-seminomatous germ cell tumors
Number of subjects: 0
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated resections and ablations for lung and liver metastases
Number of subjects: 0
Study 24415715 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trial Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC)
Number of subjects: 0
Study 20709233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 18695
Study 20709233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18695
Study 15599492 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative feedback on individual results (benchmarking)
Number of subjects: 10
Study 15599492 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-based quality circles including benchmarking
Number of subjects: 10
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Single supplements of vitamin C or E
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mixtures or single supplements of vitamins A and D, zinc, or beta-carotene
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake from supplements
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A, C, and D intake from supplements
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene, folate, and zinc intake from supplements
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education and lower body mass index
Number of subjects: 15387
Study 11588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial demographics
Number of subjects: 15387
Study 9614950 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy of the pelvic lymphatics (45 Gy for suspected metastases, 50.4 Gy for proven metastases)
Number of subjects: 0
Study 9614950 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lymphadenectomy
Number of subjects: 0
Study 9614950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy and radiotherapy
Number of subjects: 0
Study 9614950 — intervention group
Group type: COMPARATOR
Intervention: Elective radiotherapy of pelvic lymphatics
Number of subjects: 0
Study 9614950 — intervention group
Group type: COMPARATOR
Intervention: RTOG 75-06 study
Number of subjects: 0
Study 7863731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (Janssen) given twice daily for three days
Number of subjects: 0
Study 7863731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (Janssen) single-dose treatment
Number of subjects: 0
Study 7863731 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole (Nordia)
Number of subjects: 0
Study 2491829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate 1200 mg daily
Number of subjects: 54
Study 2491829 — intervention group
Group type: COMPARATOR
Intervention: No lithium (Control)
Number of subjects: 54
Study 182014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary irradiation
Number of subjects: 91
Study 182014 — intervention group
Group type: COMPARATOR
Intervention: External beam irradiation
Number of subjects: 91
Study 29106693 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized metacognitive therapy (MCT+)
Number of subjects: 92
Study 29106693 — intervention group
Group type: COMPARATOR
Intervention: CogPack (neuropsychological training)
Number of subjects: 92
Study 26526324 — intervention group
Group type: EXPERIMENTAL
Intervention: High number of different sexual partners (vaginal and oral)
Number of subjects: 310
Study 26526324 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 310
Study 26526324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 310
Study 25139178 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75 mg
Number of subjects: 17
Study 25139178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22515871 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction counseling with on-site rapid HIV testing
Number of subjects: 1281
Study 22515871 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information about testing only with on-site rapid HIV testing
Number of subjects: 1281
Study 22515871 — intervention group
Group type: COMPARATOR
Intervention: Referral for off-site HIV testing
Number of subjects: 1281
Study 20723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward probability revision
Number of subjects: 0
Study 20723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward probability revision
Number of subjects: 0
Study 20723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher probability estimate than previous speaker
Number of subjects: 0
Study 20723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower probability estimate than previous speaker
Number of subjects: 0
Study 20723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of probability phrases for two different suspects
Number of subjects: 0
Study 18784543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 26
Study 18784543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16029401 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. paracetamol 15 mg.kg(‐1)
Number of subjects: 183
Study 16029401 — intervention group
Group type: COMPARATOR
Intervention: propacetamol 30 mg.kg(‐1)
Number of subjects: 183
Study 12505969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 2% lidocaine sprayed down the ETT 5 min before extubation (Group 2)
Number of subjects: 75
Study 12505969 — intervention group
Group type: COMPARATOR
Intervention: No drug (Group 1)
Number of subjects: 75
Study 12505969 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (IVL) 3 min before extubation (Group 3)
Number of subjects: 75
Study 12505969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine sprayed down the ETT (Group 2)
Number of subjects: 75
Study 12505969 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 75
Study 12212217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 30
Study 12212217 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1 mg.kg‐1 combined with Ketamine
Number of subjects: 30
Study 8624760 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV (Zidovudine)
Number of subjects: 245
Study 8624760 — intervention group
Group type: COMPARATOR
Intervention: ddI (Didanosine)
Number of subjects: 245
Study 8624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation methods (carrying forward last observed count, regression models, decline assumption)
Number of subjects: 245
Study 1892239 — intervention group
Group type: EXPERIMENTAL
Intervention: CLS 2210
Number of subjects: 100
Study 1892239 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no CLS 2210)
Number of subjects: 100
Study 6223484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell nail
Number of subjects: 134
Study 6223484 — intervention group
Group type: COMPARATOR
Intervention: Hook-pins
Number of subjects: 134
Study 30815706 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced client-centered approach
Number of subjects: 237
Study 30815706 — intervention group
Group type: COMPARATOR
Intervention: Not receiving enhanced client-centered approach
Number of subjects: 237
Study 30815706 — intervention group
Group type: COMPARATOR
Intervention: Home rehabilitation (control group)
Number of subjects: 237
Study 30204574 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 55
Study 30204574 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 55
Study 26977860 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 52
Study 26977860 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 52
Study 25135803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in a monitoring program for CKD patients, including daily follow-up and recommendations for dose adjustments of nephrotoxic drugs.
Number of subjects: 249
Study 25135803 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard monitoring of renal function at admission and discharge without pharmacist intervention.
Number of subjects: 249
Study 21903744 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioFit Internet-based expert system
Number of subjects: 223
Study 21903744 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 223
Study 21186908 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming (implicit memory)
Number of subjects: 0
Study 21186908 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-system model prediction
Number of subjects: 0
Study 17667566 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 100
Study 17667566 — intervention group
Group type: COMPARATOR
Intervention: C‐reactive protein
Number of subjects: 100
Study 17667566 — intervention group
Group type: COMPARATOR
Intervention: White blood cell count
Number of subjects: 100
Study 17667566 — intervention group
Group type: COMPARATOR
Intervention: Interleukins 6 and 8
Number of subjects: 100
Study 16221223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ADMA concentration
Number of subjects: 93
Study 11834952 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human nerve growth factor (placebo-controlled)
Number of subjects: 236
Study 11834952 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 236
Study 10195377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 13
Study 10195377 — intervention group
Group type: COMPARATOR
Intervention: Glucose ingestion
Number of subjects: 13
Study 7756047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study 7756047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pre-treatment alkaline phosphatase and alkaline phosphatase half-life
Number of subjects: 0
Study 7756047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pre-treatment hydroxyproline and hydroxyproline half-life
Number of subjects: 0
Study 7756047 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of half-lives of markers of bone turnover
Number of subjects: 0
Study 2319516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 'minipulse' (100 mg) methylprednisolone (MP) therapy
Number of subjects: 36
Study 2319516 — intervention group
Group type: COMPARATOR
Intervention: Standard pulse (1000 mg) methylprednisolone (MP) therapy
Number of subjects: 36
Study 583022 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg treptilamine i.v.
Number of subjects: 20
Study 583022 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg treptilamine p.o.
Number of subjects: 20
Study 583022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31866190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene (1 cap, 25 mg three times daily, or two times daily if not tolerable)
Number of subjects: 300
Study 31866190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 300
Study 31461575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 213
Study 28109874 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable‐polymer zotarolimus‐eluting stent
Number of subjects: 2999
Study 28109874 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable‐polymer biolimus‐eluting stent
Number of subjects: 2999
Study 25523054 — intervention group
Group type: EXPERIMENTAL
Intervention: r-tPA plus eptifibatide
Number of subjects: 85
Study 24524031 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 98
Study 24524031 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 98